The Supervisory Board of Sartorius AG has extended the appointment of Dr. René Faber as a member of the Executive Board by a five-year period, through December 31, 2031. The decision was made at the board's meeting on March 26, 2026, reflecting confidence in Faber's leadership and the strategic direction of the company's Bioprocess Solutions Division.
Dr. René Faber, 50, holds a Ph.D. in polymer chemistry from the Technical University of Munich. He began his career at Sartorius as a scientist in 2002 and has held various management positions before being appointed to the Executive Board in January 2019. In his current role, he oversees the Bioprocess Solutions Division, which is a key growth driver for the company.
Sartorius is a leading international partner to the biopharmaceutical research and manufacturing industries. The Bioprocess Solutions Division provides single-use solutions for the production of biotech drugs, vaccines, and cell and gene therapies, aiming for safer, faster, and more sustainable manufacturing. The Lab Products & Services Division focuses on laboratory instruments and consumables for pharmaceutical, biopharmaceutical, and academic research.
The extension of Faber's appointment ensures continuity in the company's strategic initiatives, particularly as Sartorius continues to expand its portfolio through acquisitions and innovation. In 2025, the company reported sales revenue of approximately 3.5 billion euros and employs over 14,000 people across around 60 production and sales locations worldwide.
For more details on Dr. Faber's background, a curriculum vitae is available on the Sartorius website. The company also provided its financial calendar for 2026, including the publication of first quarter results on April 23, half-year results on July 23, and nine-month results on October 22. Additional information can be found on the original release or by visiting Sartorius's newsroom.
